References

Microsampling

 

• Clinical validation of a capillary blood home-based self-sampling technique for monitoring of infliximab, vedolizumab, and C-reactive protein concentrations in patients with inflammatory bowel disease. Otten, Tim et al. Inflammatory bowel diseases, izad103. 2 Jun. 2023.

 

• Augmenting digital health by self-sampling at home via finger prick: a feasibility study in 3034 participants of a prospective cohort study. Besten, Yaelle et al. In submission. 2023

 

• Fingerprick blood samples to measure serum natalizumab concentrations. Toorop, Alyssa A et al. Mult Scler. 2022 Nov 30:13524585221136448. doi: 10.1177/13524585221136448. Epub ahead of print. PMID: 36448735.

 

• Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients. Zijlstra, Marieke et al. Journal of pediatric gastroenterology and nutrition vol. 72,1 (2021): 56-60. doi:10.1097/MPG.0000000000002906

 

• Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. Berends, Sophie E et al. Therapeutic drug monitoring vol. 42,2 (2020): 289-294. doi:10.1097/FTD.0000000000000686

 

• Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. Berends, Sophie E et al. British journal of clinical pharmacology vol. 85,7 (2019): 1544-1551. doi:10.1111/bcp.13939

 

• Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra^® microsampler vs dried blood spot. Bloem, Karien et al. Bioanalysis vol. 10,11 (2018): 815-823. doi:10.4155/bio-2018-0010

 

• Dried blood spots from finger prick facilitate therapeutic drug monitoring of adalimumab and anti-adalimumab in patients with inflammatory diseases. Kneepkens, Eva L et al. British journal of clinical pharmacology vol. 83,11 (2017): 2474-2484. doi:10.1111/bcp.13371

 

Finger prick implementation during COVID-19 studies

• Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands. Boekel L et al. Lancet Rheumatol. 2023 Jul;5(7):e375-e385. doi: 10.1016/S2665-9913(23)00127-3. Epub 2023 May 31. PMID: 37398978; PMCID: PMC10292827.

 

• Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity. van Dam KPJ, Volkers AG et al. BMC Infect Dis. 2023 May 17;23(1):332. doi: 10.1186/s12879-023-08298-6. PMID: 37198536; PMCID: PMC10189216.

 

• SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis. van Kempen ZLE et al. J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):280-283. doi: 10.1136/jnnp-2022-330100. Epub 2022 Dec 23. PMID: 36564175.

 

• Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases. Wieske L et al. Ann Rheum Dis. 2023 Jan 31:ard-2022-223464. doi: 10.1136/ard-2022-223464. Epub ahead of print. PMID: 36720583.

 

• Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Stalman EW et al. Ann Rheum Dis. 2022 Dec;81(12):1757-1766. doi: 10.1136/ard-2022-222904. Epub 2022 Sep 5. PMID: 36357161.

 

• Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy. Bouwmans P, et al. Clin Kidney J. 2022 Nov 24;16(3):528-540. doi: 10.1093/ckj/sfac249. PMID: 36865021; PMCID: PMC9972832.

 

• Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination. van Dam KPJ et al.  Front Neurol. 2022 Nov 10;13:1032830. doi: 10.3389/fneur.2022.1032830. PMID: 36438945; PMCID: PMC9686308.

 

• SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. Boekel L, et al. Lancet Rheumatol. 2022 Nov;4(11):e747-e750. doi: 10.1016/S2665-9913(22)00221-1. Epub 2022 Aug 23. PMID: 36034738; PMCID: PMC9398211.

 

• Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. Verstegen, Niels J M et al. eLife vol. 11 e77969. 15 Jul. 2022, doi:10.7554/eLife.77969

 

• Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. Boekel, L et al. RMD Open. 2022 Apr;8(1):e002035. doi: 10.1136/rmdopen-2021-002035. PMID: 35383121; PMCID: PMC8983412.

 

• Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Wieske, Luuk et al. The Lancet. Rheumatology vol. 4,5 (2022): e338-e350. doi:10.1016/S2665-9913(22)00034-0

 

• Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Boekel, Laura et al. The Lancet. Rheumatology vol. 3,11 (2021): e778-e788. doi:10.1016/S2665-9913(21)00222-8

 

• SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort. Van Kempen, Zoé L E et al. JAMA neurology vol. 78,7 (2021): 880-882. doi:10.1001/jamaneurol.2021.1364